Philadelphia chromosome-positive B-acute lymphoblastic leukemia in Egyptian patients / Fatma Gamal Abdel Nasser Hassan ; Supervised Somaya Eldeeb , Neemat Kassem , Raafat A. Malek
Material type: TextLanguage: English Publication details: Cairo : Fatma Gamal Abdel Nasser Hassan , 2017Description: 68 P. : charts ; 25cmOther title:- كروموسوم فيلادلفيا الإيجابى فى سرطان الدم الليمفاوى- ب الحاد فى المرضى المصريين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.12.21.M.Sc.2017.Fa.P (Browse shelf(Opens below)) | Not for loan | 01010110075058000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.12.21.M.Sc.2017.Fa.P (Browse shelf(Opens below)) | 75058.CD | Not for loan | 01020110075058000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Zoology
Background: Little evidence exists regarding the prevalence, clinical outcomes and molecular response of adult patients with philadelphia chromosome (Ph) positive versus Ph negative B-Acute lymphoblastic leukemia (B-ALL) in our country. The aim of our study: Was to explore the prevalence of Ph by detection of minor bcr-abl gene (mbcr-abl) on it by qRT-PCR in Egyptian B-ALL cases, compare the Ph positive B-ALL patients with negative ones regarding baseline characteristics before treatment, detect the hematological and molecular responses in positive patients after receiving tyrosine kinase inhibitor (TKI) accompanied with classic chemotherapy, and compare treatment outcome and survival in both groups of patients. Patients and methods: Adult B-ALL patients presented to clinical oncology department at Cairo university were enrolled in the study during the period from January 2013 till January 2016. All patients underwent clinical assessment and baseline investigations including immunophenotyping by flow cytometry in addition to quantitative assessment of mbcr-abl gene expression using quantitative real-time polymerase chain reaction (qRT-PCR). Treatment and survival data were also collected. All patients received classic B-ALL treatment in addition to TKI (Imatinib) in Ph positive cases
Issued also as CD
There are no comments on this title.